This article is a brief overview of basic and clinical research on CCR4 and its ligands, which has eventually led to the development of a humanized defucosylated anti-CCR4 antibody 'Mogamulizumab' for treatment of relapsed/refractory ATL and CTCLs.

CCR4 is a chemokine receptor selectively expressed on normal T cell subsets such as type 2 helper T cells, skin-homing T cells and regulatory T cells, and on skin-associated T cell malignancies such as adult T cell leukemia/lymphoma (ATLL), which is ...

Dec 24, 2024 · CCR4 (C-C Motif Chemokine Receptor 4) is a Protein Coding gene. Diseases associated with CCR4 include Mycosis Fungoides and Peripheral T-Cell Lymphoma. Among its related pathways are Class A/1 (Rhodopsin-like receptors) and GPCR downstream signalling.

Aug 2, 2014 · This article is a brief overview of basic and clinical research on CCR4 and its ligands, which has eventually led to the development of a humanized defucosylated anti-CCR4 antibody ‘Mogamulizumab’ for treatment of relapsed/refractory ATL and CTCLs.

Nov 4, 2021 · CCR4 is a chemokine receptor mainly expressed by T cells. It is the receptor for two CC chemokine ligands, CCL17 and CCL22. Originally, the expression of CCR4 was described as highly selective for helper T type 2 (Th2) cells.

CCR4 is a chemokine receptor found on a specific type of cells in patients with HL, and it is being targeted for treatment using a defucosylated antibody. AI generated definition based on: Diagnostic Immunohistochemistry (Third Edition), 2011

Recent studies in budding yeast have identified novel roles for Ccr4-Not as a key regulator of core nutrient signaling pathways that control cell growth and proliferation, including signaling through the mechanistic target of rapamycin complex 1 (TORC1) pathway.

The chemokine receptor CCR4 is a seven trans-membrane G protein-coupled cell surface receptor molecule (alternatively designated CD194) with selective expression on cells of the hematopoietic system (reviewed in 1, 2).

Our proprietary drug discovery and development engine has identified the cell surface receptor CCR4 (C-C Motif Chemokine Receptor 4) as a drug target that potentially has broad applicability in oncology and allergic inflammatory diseases.

Findings suggest that C-C motif chemokine receptor 4 (CCR4) may be a potential new diagnostic and prognostic marker in hepatocellular carcinoma (HCC), and targeting CCR4 may be a potential therapeutic option for blocking HCC metastasis